Table 3.
The prognostic value of tumor-infiltrating CD8+ T-cells/PD-L1 axis in high-grade glioma patients.
| First author, year | Country | Sample size | Prognostic value | P-value | HR and 95%CI | Endpoint | Cancer treatment history |
|---|---|---|---|---|---|---|---|
| Plant, 2018 ( 22 ) | USA | 27 | The level of tumor-infiltrating CD8+ T-cells is not statistically associated with OS. | P=0.8 | 1.0190, and 0.8743-1.1637 | OS | Not provided. |
| Jan, 2018 ( 21 ) | Taiwan | 20 | The level of tumor-infiltrating CD8+ T-cells is not statistically associated with OS. | P=0.5 | 0.725, and 0.284–1.853 | OS | Resection and chemo-radiotherapy |
| Jan, 2018 ( 21 ) | Taiwan | 20 | The level of tumor-infiltrating CD8+ T-cells is not statistically associated with PFS. | P=0.73 | 1.082, and 0.688–1.703 | PFS | Resection and chemo-radiotherapy |
| Jan, 2018 ( 21 ) | Taiwan | 27 | The level of tumor-infiltrating CD8+ T-cells is not statistically associated with OS. | P=0.31 | 1.55, and 0.667–3.601 | OS | Resection, chemo-radiotherapy, and autologous dendritic cell/tumor antigen vaccine |
| Jan, 2018 ( 21 ) | Taiwan | 27 | The level of tumor-infiltrating CD8+ T-cells is not statistically associated with PFS. | P=0.36 | 1.489, and 0.640–3.461 | PFS | Resection, chemo-radiotherapy, and autologous dendritic cell/tumor antigen vaccine |
| Su, 2020 ( 16 ) | China | 47 | The higher level of tumor-infiltrating CD8+ T-cells is associated with improved OS. | P<0.05 | Not provided | OS | Surgery |
| Miyazak, 2017 ( 15 ) | Japan | 16 | The higher level of Tumor-infiltrating CD8+ T-cells is not associated with PFS. | P=0.495 | Not provided | PFS | Treated with surgery, radiation, temozolomide, and four patients received a cancer vaccine |
| Miyazak, 2017 ( 15 ) | Japan | 16 | The higher level of tumor-infiltrating CD8+ T-cells is associated with inferior OS. | P=0.017 | Not provided | OS | Treated with surgery, radiation, temozolomide, and four patients received a cancer vaccine |
| Miyazak, 2017 ( 15 ) | Japan | 16 | The higher level of tumor-infiltrating CD8+ T-cells is associated with inferior survival from the second surgery. | P=0.005 | Not provided | Survival from the second surgery | Treated with surgery, radiation, temozolomide, and four patients received a cancer vaccine |
| Berghoff, 2015 ( 20 ) | Austria | 135 | The membranous PD-L1 is not statistically associated with OS. | P=0.724 | Not provided | OS | Except for the five unknown patients, others were on chemotherapy/investigational agents. |
| Berghoff, 2015 ( 20 ) | Austria | 135 | The diffuse/fibrillary PD-L1 is not statistically associated with OS. | P=0.921 | Not provided | OS | Except for the five unknown patients, others were on chemotherapy/investigational agents. |
| Plant, 2018 ( 22 ) | USA | 27 | The tumoral PD-L1 is not statistically associated with OS. | P=0.6 | 1.0080, and 0.9789 - 1.0371 | OS | Not appropriately provided. |
| Jan, 2018 ( 21 ) | Taiwan | 20 | The fibrillary/membranous PD-L1 is not statistically associated with OS. | P=0.38 | 0.654, and 0.254 - 1.685 | OS | Resection and chemoradiotherapy |
| Jan, 2018 ( 21 ) | Taiwan | 20 | The fibrillary/membranous PD-L1 is not statistically associated with PFS. | P=0.5 | 1.435, and 0.498 - 4.137 | PFS | Resection and chemoradiotherapy |
| Jan, 2018 ( 21 ) | Taiwan | 27 | The fibrillary/membranous PD-L1 is not statistically associated with OS. | P=0.1 | 0.354, and 0.103 - 1.219 | OS | Resection, chemo-radiotherapy, and autologous dendritic cell/tumor antigen vaccine |
| Jan, 2018 ( 21 ) | Taiwan | 27 | The fibrillary/membranous PD-L1 is not statistically associated with PFS. | P=0.248 | 0.528, and 0.178 - 1.563 | PFS | Resection, chemo-radiotherapy, and autologous dendritic cell/tumor antigen vaccine |
| Su, 2019 ( 16 ) | China | 47 | The PD-L1 overexpression is associated with inferior OS. | P=0.0119 | Not provided | OS | Surgery |
| Miyazak, 2017 ( 15 ) | Japan | 16 | The tumoral PD-L1 is not statistically associated with PFS. | P=0.095 | Not provided | PFS | Treated with surgery, radiation, temozolomide, and four patients received a cancer vaccine |
| Miyazak, 2017 ( 15 ) | Japan | 16 | The tumoral PD-L1 is not statistically associated with OS. | P=0.356 | Not provided | OS | Treated with surgery, radiation, temozolomide, and four patients received a cancer vaccine |
| Miyazak, 2017 ( 15 ) | Japan | 16 | The tumoral PD-L1 is not statistically associated with survival from the second surgery. | P=0.418 | Not provided | Survival from the second surgery | Treated with surgery, radiation, temozolomide, and four patients received a cancer vaccine |
OS, Overall survival; PD-L1, Programmed death-ligand 1; PFS, Progression-free survival; HR, Hazard ratio; CI, Confidence interval; and CD, Cluster of differentiation.